Northwestern Mutual Wealth Management Co. Has $8.10 Million Stock Position in Sanofi $SNY

Northwestern Mutual Wealth Management Co. raised its holdings in Sanofi (NASDAQ:SNY) by 307.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 167,096 shares of the company’s stock after buying an additional 126,048 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Sanofi were worth $8,097,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Atria Investments Inc grew its holdings in shares of Sanofi by 13.1% during the 4th quarter. Atria Investments Inc now owns 132,716 shares of the company’s stock worth $6,431,000 after purchasing an additional 15,416 shares in the last quarter. Independent Advisor Alliance grew its holdings in shares of Sanofi by 65.9% during the 4th quarter. Independent Advisor Alliance now owns 8,450 shares of the company’s stock worth $409,000 after purchasing an additional 3,356 shares in the last quarter. World Investment Advisors grew its holdings in shares of Sanofi by 8.1% during the 4th quarter. World Investment Advisors now owns 73,792 shares of the company’s stock worth $3,449,000 after purchasing an additional 5,553 shares in the last quarter. Glass Wealth Management Co LLC grew its holdings in shares of Sanofi by 2.4% during the 4th quarter. Glass Wealth Management Co LLC now owns 36,100 shares of the company’s stock worth $1,749,000 after purchasing an additional 850 shares in the last quarter. Finally, Trek Financial LLC acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $213,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Price Performance

Sanofi stock opened at $44.29 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. The company has a market capitalization of $108.02 billion, a PE ratio of 12.37, a price-to-earnings-growth ratio of 1.11 and a beta of 0.35. Sanofi has a one year low of $42.33 and a one year high of $53.03. The business has a 50 day simple moving average of $45.58 and a 200 day simple moving average of $47.23.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th will be given a $2.4225 dividend. This represents a yield of 559.0%. The ex-dividend date is Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio is presently 49.16%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SNY. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Monday, April 20th. Morgan Stanley set a $52.00 target price on Sanofi in a research report on Friday, May 1st. Citigroup restated a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Hold” and a consensus target price of $51.00.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.